BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29856004)

  • 1. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.
    Cullberg M; Arfvidsson C; Larsson B; Malmgren A; Mitchell P; Wählby Hamrén U; Wray H
    Drugs R D; 2018 Jun; 18(2):149-159. PubMed ID: 29856004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
    Falcoz C; Jenkins JM; Bye C; Hardman TC; Kenney KB; Studenberg S; Fuder H; Prince WT
    J Clin Pharmacol; 2002 Aug; 42(8):887-98. PubMed ID: 12162471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
    Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
    Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
    Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
    J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
    Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
    J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
    Lentini S; Heinig R; Kimmeskamp-Kirschbaum N; Wensing G
    Fundam Clin Pharmacol; 2016 Apr; 30(2):172-84. PubMed ID: 26604072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.
    Kakuda TN; Sekar V; Lavreys L; De Paepe E; Stevens T; Vanstockem M; Vangeneugden T; Hoetelmans RM
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):346-52. PubMed ID: 27129006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects.
    Chen JJ; Hewitt LA
    Drugs R D; 2018 Mar; 18(1):77-86. PubMed ID: 29392574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.
    Kim E; Kim A; Yi S; Kim YK; Jang SB; Byun HM; Yoon SH; Cho JY; Jang IJ; Yu KS; Lee S
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1261-1272. PubMed ID: 29907887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
    Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
    Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.
    Kanefendt F; Thuß U; Becka M; Boxnick S; Berse M; Schultz A; Otto C
    Clin Pharmacol Drug Dev; 2019 May; 8(4):467-479. PubMed ID: 29878583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
    Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
    Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
    Undre N; Dickinson J
    BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.